📰 Altavant Sciences News
Page 2 - Altavant Sciences News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Altavant Sciences. Real-time updates on events, politics, business and more.
May 6, 2022
/PRNewswire/ -- Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases,...
May 4, 2022
/PRNewswire/ -- DelveInsights Chronic Pulmonary Hypertension Market Insights report includes a comprehensive understanding of current treatment practices,...
May 4, 2022
The Chronic Pulmonary Hypertension market size is anticipated to surge owing to extensive research and development activities of pharmaceutical companies, along with the launch of various multiple-stage
May 2, 2022
Press release content from PR Newswire. The AP news staff was not involved in its creation.
April 25, 2022
Press release content from PR Newswire. The AP news staff was not involved in its creation.
April 25, 2022
/PRNewswire/ -- Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases,...
April 25, 2022
/PRNewswire/ -- Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases,...
March 15, 2022
/PRNewswire/ -- The "Global Respiratory Partnering 2010-2021: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.coms offering....
March 15, 2022
/PRNewswire/ -- The "Global Respiratory Partnering 2010-2021: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.coms offering....
February 24, 2022
Currently, major driving factors for Bronchiolitis Obliterans Syndrome market include development of potential therapies such as Zambon's Phase III asset, Liposomal cyclosporine A, under clinical